SCHEMBL22235147

SCHEMBL22235147

CCOc1cc2nc(C3CC(F)(F)C3)cn2cc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.40
MAP3K12 Q12852 1/20 0.34
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SCN9A Q15858 1/20 0.32
RIPK2 O43353 2/20 0.31
KCNH2 Q12809 1/20 0.31
PIK3CA P42336 1/20 0.30
NPC1 O15118 1/20 0.30
USP2 O75604 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22235013 0.86 IRAK4 (0.48) IRAK4MAP3K12HSD17B10KDM4EMEN1
SCHEMBL22234932 0.85 IRAK4 (0.40) IRAK4MAP3K12SCN9AKCNH2
Hydrochloric Acid SCHEMBL22235194 0.85 IRAK4 (0.47) IRAK4MAP3K12HSD17B10KDM4EMEN1
SCHEMBL22259295 0.83 IRAK4 (0.47) IRAK4HSD17B10ALDH1A1KCNH2NPC1
SCHEMBL22234883 0.81 IRAK4 (0.52) IRAK4MAP3K12HSD17B10KDM4EMEN1
SCHEMBL22234689 0.77 IRAK4 (0.36) IRAK4MAP3K12HSD17B10KDM4EMEN1
SCHEMBL22259294 0.76 IRAK4 (0.40) IRAK4KCNH2
SCHEMBL22235133 0.73 KDM4E (0.40) IRAK4HSD17B10KDM4EMEN1ALDH1A1
SCHEMBL22235239 0.71 SUV39H2 (0.39) IRAK4HSD17B10KDM4EALDH1A1MAPT
SCHEMBL22234581 0.70 IRAK4 (0.48) IRAK4HSD17B10MEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
EP-3911652-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS Biogen MA Inc. (US) 2021-11-24 EP disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 IRAK4 1/4885MAP3K12 49/4885HSD17B10 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.